Challenges for cancer vaccine development.
The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines.
Tabi
Z
Z
Department of Oncology and Palliative Medicine, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK. zsuzsanna.tabi@velindre-tr.wales.nhs.uk
Man
S
S
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines